Stay updated with breaking news from Gil Efron. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal/IRI/5FU/LV vs. standard-of-care(SoC) based on preliminary interim dataProlongation of
Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study
NT219 found to suppress cancer stem cells that promote drug resistance to KRASG12C and KRASG12D inhibitors and solid tumor recurrence Potential biomarkers for treatment with NT219 detected in...
NT219 recommended dose established, anti-tumor activity demonstrated REHOVOT, Israel, Feb. 13, 2024 -- Purple Biotech Ltd. , a clinical-stage company developing first-in-class therapies...
REHOVOT, Israel, Feb. 01, 2024 -- Purple Biotech Ltd. , a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune...